Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.
D-dimer
antifibrinolytic drug
fibrinogen
fibrinolysis
plasmin
plasmin–antiplasmin complex
postpartum haemorrhage
thrombin
tranexamic acid
Journal
British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
29
04
2022
revised:
31
07
2022
accepted:
25
08
2022
pubmed:
16
10
2022
medline:
23
11
2022
entrez:
15
10
2022
Statut:
ppublish
Résumé
The optimal dose of tranexamic acid to inhibit hyperfibrinolysis in postpartum haemorrhage is unclear. Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Cesarean Delivery (TRACES) was a double-blind, placebo-controlled, randomised, multicentre dose-ranging study to determine the dose-effect relationship for two regimens of intravenous tranexamic acid vs placebo. Women experiencing postpartum haemorrhage during Caesarean delivery were randomised to receive placebo (n=60), tranexamic acid 0.5 g (n=57), or tranexamic acid 1 g i.v. (n=58). Biomarkers of fibrinolytic activation were assayed at five time points, with inhibition of hyperfibrinolysis defined as reductions in the increase over baseline in D-dimer and plasmin-antiplasmin levels and in the plasmin peak time. In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline [95% confidence interval] of 93% [68-118] for D-dimer level at 120 min and 56% [25-87] for the plasmin-antiplasmin level at 30 min. A dose of tranexamic acid 1 g was associated with smaller increases over baseline (D-dimers: 38% [13-63] [P=0.003 vs placebo]; plasmin-antiplasmin: -2% [-32 to 28] [P=0.009 vs placebo]). A dose of tranexamic acid 0.5 g was less potent, with non-significant reductions (D-dimers: 58% [32-84] [P=0.06 vs placebo]; plasmin-antiplasmin: 13% [18-43] [P=0.051]). Although both tranexamic acid doses reduced the plasmin peak, reduction in plasmin peak time was significant only for the 1 g dose of tranexamic acid. Fibrinolytic activation was significantly inhibited by a dose of intravenous tranexamic acid 1 g but not 0.5 g. Pharmacokinetic-pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage. NCT02797119.
Sections du résumé
BACKGROUND
The optimal dose of tranexamic acid to inhibit hyperfibrinolysis in postpartum haemorrhage is unclear. Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Cesarean Delivery (TRACES) was a double-blind, placebo-controlled, randomised, multicentre dose-ranging study to determine the dose-effect relationship for two regimens of intravenous tranexamic acid vs placebo.
METHODS
Women experiencing postpartum haemorrhage during Caesarean delivery were randomised to receive placebo (n=60), tranexamic acid 0.5 g (n=57), or tranexamic acid 1 g i.v. (n=58). Biomarkers of fibrinolytic activation were assayed at five time points, with inhibition of hyperfibrinolysis defined as reductions in the increase over baseline in D-dimer and plasmin-antiplasmin levels and in the plasmin peak time.
RESULTS
In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline [95% confidence interval] of 93% [68-118] for D-dimer level at 120 min and 56% [25-87] for the plasmin-antiplasmin level at 30 min. A dose of tranexamic acid 1 g was associated with smaller increases over baseline (D-dimers: 38% [13-63] [P=0.003 vs placebo]; plasmin-antiplasmin: -2% [-32 to 28] [P=0.009 vs placebo]). A dose of tranexamic acid 0.5 g was less potent, with non-significant reductions (D-dimers: 58% [32-84] [P=0.06 vs placebo]; plasmin-antiplasmin: 13% [18-43] [P=0.051]). Although both tranexamic acid doses reduced the plasmin peak, reduction in plasmin peak time was significant only for the 1 g dose of tranexamic acid.
CONCLUSIONS
Fibrinolytic activation was significantly inhibited by a dose of intravenous tranexamic acid 1 g but not 0.5 g. Pharmacokinetic-pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage.
CLINICAL TRIAL REGISTRATION
NCT02797119.
Identifiants
pubmed: 36243576
pii: S0007-0912(22)00504-9
doi: 10.1016/j.bja.2022.08.033
pmc: PMC9748994
pii:
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Antifibrinolytic Agents
0
Fibrinolysin
EC 3.4.21.7
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02797119']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
937-945Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Haematologica. 2020 May;105(5):1201-1205
pubmed: 32336684
J Thromb Haemost. 2021 Jan;19(1):221-232
pubmed: 33001565
N Engl J Med. 2018 Aug 23;379(8):731-742
pubmed: 30134136
Anesth Analg. 2010 Feb 1;110(2):350-3
pubmed: 19996135
BJOG. 2019 Jan;126(1):83-93
pubmed: 29920912
Nephrol Dial Transplant. 2020 Sep 1;35(9):1538-1546
pubmed: 30805631
Anaesthesia. 2018 Jun;73(6):719-729
pubmed: 29411358
N Engl J Med. 2021 Apr 29;384(17):1623-1634
pubmed: 33913639
Lancet. 2020 Jun 20;395(10241):1927-1936
pubmed: 32563378
Stat Med. 2009 Sep 10;28(20):2509-30
pubmed: 19610129
Trials. 2018 Mar 1;19(1):148
pubmed: 29490682
Lancet. 2016 Jan 30;387(10017):462-74
pubmed: 26584737
Crit Care. 2011;15(2):R117
pubmed: 21496253
BMC Med Res Methodol. 2005 Nov 03;5:35
pubmed: 16269081
Pharmaceutics. 2022 Mar 06;14(3):
pubmed: 35335955
Lancet. 2017 May 27;389(10084):2105-2116
pubmed: 28456509
Am J Obstet Gynecol. 2021 Jul;225(1):85.e1-85.e11
pubmed: 33248975
Trials. 2018 Mar 1;19(1):149
pubmed: 29490690
Br J Clin Pharmacol. 2021 Sep;87(9):3531-3541
pubmed: 33576009
Biometrics. 1982 Sep;38(3):715-24
pubmed: 7171697
JAMA Surg. 2020 Oct 05;:
pubmed: 33016996
Haemophilia. 2012 Jul;18(4):630-8
pubmed: 22404435
Wellcome Open Res. 2018 Aug 15;3:100
pubmed: 30345385
Hematology. 2011 Nov;16(6):327-36
pubmed: 22183066
Am J Obstet Gynecol. 1990 May;162(5):1158-63
pubmed: 2140236
Eur J Pharm Sci. 2020 Oct 1;153:105486
pubmed: 32717429
Eur J Obstet Gynecol Reprod Biol. 2016 Mar;198:12-21
pubmed: 26773243
BMC Pregnancy Childbirth. 2018 May 9;18(1):143
pubmed: 29743045
Cochrane Database Syst Rev. 2018 Feb 20;2:CD012964
pubmed: 29462500
Br J Anaesth. 2016 May;116(5):641-8
pubmed: 27106967